Multiple Myeloma  >>  Caprelsa (vandetanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT00047788: Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer

Completed
2
30
US, Canada
ZD6474, VEGF-receptor tyrosine kinase (KDR)
Genzyme, a Sanofi Company
Multiple Myeloma
 
05/04

Download Options